111 related articles for article (PubMed ID: 25683936)
21. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
22. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
[TBL] [Abstract][Full Text] [Related]
24. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.
Fenton C; Patel A; Dinauer C; Robie DK; Tuttle RM; Francis GL
Thyroid; 2000 Apr; 10(4):349-57. PubMed ID: 10807064
[TBL] [Abstract][Full Text] [Related]
25. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
26. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
27. Predicting lymph node metastasis in patients with papillary thyroid carcinoma by vascular index on power Doppler ultrasound.
Lee JH; Shin HJ; Yoon JH; Kim EK; Moon HJ; Lee HS; Kwon HJ; Kwak JY
Head Neck; 2017 Feb; 39(2):334-340. PubMed ID: 27704649
[TBL] [Abstract][Full Text] [Related]
28. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
30. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
Bauer AJ; Terrell R; Doniparthi NK; Patel A; Tuttle RM; Saji M; Ringel MD; Francis GL
Thyroid; 2002 Nov; 12(11):953-61. PubMed ID: 12490072
[TBL] [Abstract][Full Text] [Related]
32. Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth.
Song YS; Kim MJ; Sun HJ; Kim HH; Shin HS; Kim YA; Oh BC; Cho SW; Park YJ
Clin Cancer Res; 2019 Jan; 25(1):414-425. PubMed ID: 30314969
[TBL] [Abstract][Full Text] [Related]
33. Angiogenic and lymphangiogenic profiles in histological variants of papillary thyroid carcinoma.
Skuletic V; Radosavljevic GD; Pantic J; Markovic BS; Jovanovic I; Jankovic N; Petrovic D; Jevtovic A; Dzodic R; Arsenijevic N
Pol Arch Intern Med; 2017 Jun; 127(6):429-437. PubMed ID: 28425432
[TBL] [Abstract][Full Text] [Related]
34. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
[TBL] [Abstract][Full Text] [Related]
35. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma.
Hsueh C; Lin JD; Wu IC; Chao TC; Yu JS; Liou MJ; Yeh CJ
J Surg Oncol; 2011 Apr; 103(5):395-9. PubMed ID: 21400522
[TBL] [Abstract][Full Text] [Related]
37. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
38. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-mediated siRNA targeting NOB1 inhibits tumor growth and enhances radiosensitivity of human papillary thyroid carcinoma in vitro and in vivo.
Meng W; Wang PS; Liu J; Xue S; Wang GM; Meng XY; Chen G
Oncol Rep; 2014 Dec; 32(6):2411-20. PubMed ID: 25231838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]